Asciminib Provides MMR Benefits vs SOC TKIs in Newly Diagnosed Ph+ CML
January 8th 2024Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Read More
Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC
January 4th 2024Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.
Read More
POSEIDON Update Confirms OS Benefit of Tremelimumab/Durvalumab Plus Chemo in mNSCLC
January 3rd 2024A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.
Read More
The Intersections of Career Direction and Personal Connections
December 27th 2023With perseverance, compassion, and energy, Ann H. Partridge, MD, MPH, has devoted her career to shrinking the gaps in research and care for young women with breast cancer and improving their outcomes and quality of life along the way.
Read More
Combination Regimens Expand RCC and Prostate Cancer Treatment Armamentariums
December 26th 2023Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal agents plus androgen deprivation therapy in frontline metastatic hormone-sensitive prostate cancer.
Read More
Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer
December 22nd 2023Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.
Read More
ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment
December 21st 2023Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.
Read More
FDA Grants Breakthrough Therapy Designation to BNT323/DB-1303 in Endometrial Cancer
December 21st 2023The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.
Read More
Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care
December 18th 2023Hope Cottrill, MD, highlights practice-changing developments in endometrial cancer care, the benefits of local control with radiation in patients with locally aggressive disease, and questions that remain regarding treatment sequencing with immunotherapy.
Read More
RCC Research May Lead to SOC Improvements and Individualized Treatment Plans
December 15th 2023Marijo Bilusic, MD, PhD, highlights key insights about renal cell carcinoma that were presented at the meeting covering considerations on sequencing TKIs, the need for further research to elucidate novel therapies, and the importance of offering clinical trials to all patients with genitourinary malignancies.
Read More
SIM0270 Demonstrates Early Antitumor Activity in ER+/HER2– Advanced/Metastatic Breast Cancer
December 8th 2023The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.
Read More
Tovorafenib Induces Responses in Low-Grade Gliomas, Including Optic Pathway Gliomas
December 7th 2023Tovorafenib elicited rapid, clinically meaningful tumor responses in pediatric patients with low-grade gliomas, including those with optic pathway gliomas, regardless of prior MAPK inhibitor status.
Read More
PFS Benefit Observed With Tucatinib Plus T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.
Read More
Ovarian Cancer Research Outlines the Role of ADCs, PARP Inhibitors, and Surgery
December 4th 2023Hope Cottrill, MD, highlights key points that were presented at a State of the Science Summit meeting, including the role of bevacizumab plus PARP inhibitors in ovarian cancer management, how to manage adverse events associated with antibody-drug conjugates, and ongoing research in ovarian cancer risk reduction.
Read More